Medicare Oversight: Congressman’s Shocking Stock Move

(ProsperNews.net) – A Republican congressman with direct oversight of Medicare policy dumped his entire UnitedHealth stock position worth up to half a million dollars just weeks before the company’s shares plunged over 9 percent, raising fresh questions about whether members of Congress are profiting from privileged information unavailable to ordinary Americans.

Story Highlights

Rep. Kevin Hern sold his entire UnitedHealth stake worth $250,001–$500,000 on December 23, 2025, weeks before the stock crashed over 9% on Medicare rate news
Hern serves on the House Health Subcommittee that oversees Medicare policy and received CMS briefings before the holiday recess
The suspicious timing mirrors a broader pattern of lawmakers selling UnitedHealth stock ahead of regulatory bad news throughout 2025
Retail investors suffered significant losses while connected politicians appear to have avoided the damage through timely exits

Suspicious Timing Raises Red Flags

Rep. Kevin Hern of Oklahoma unloaded his entire UnitedHealth Group position through his family trust on December 23, 2025, just over a month before shares tanked on January 26, 2026. The stock dropped more than 9 percent after the Wall Street Journal reported the White House planned to keep Medicare reimbursement rates flat for 2027. Hern’s sale, disclosed in a filing dated January 22, came right after Centers for Medicare and Medicaid Services briefed congressional leaders on upcoming policy changes before the December holiday recess. His position on the House Subcommittee on Health, which directly oversees Medicare payment policy with CMS, gave him access to information most investors never see.

Committee Access Creates Unfair Advantage

Hern built his UnitedHealth position over three years through twelve separate purchases between October 2021 and July 2024. Despite his position being underwater at the time of sale, he exited completely just before the stock suffered an additional steep decline. This privileged access to policy briefings creates a fundamental fairness problem that undermines public trust. While hardworking Americans who invested their retirement savings in UnitedHealth watched their holdings crater, a congressman with insider knowledge walked away unscathed. Portfolio manager Weiskopf from Tidal Financial described such well-timed lawmaker stock sales as “red flags” that should warn regular investors about regulatory concerns brewing behind closed doors.

Republican On Health Committee Sells UNH Weeks Before Stock Tanks On Lower Payout Rates https://t.co/BXqY0TCdFV

— zerohedge (@zerohedge) January 27, 2026

Part of Disturbing Bipartisan Pattern

Hern’s trade fits within a troubling 2025 pattern of congressional UnitedHealth stock sales preceding bad news. Representatives from both parties, including Khanna, Cisneros, Shreve, Taylor, Moskowitz, and Bresnahan, collectively sold up to $1.2 million in UnitedHealth shares throughout 2025 as the company faced DOJ investigations over Medicare billing practices and care denials. These sales occurred after lawmakers received briefings about civil and criminal probes into the insurance giant. The coordination and timing suggest members of Congress are trading on privileged information from their oversight roles while ordinary Americans remain in the dark until stock prices collapse. This represents exactly the kind of swamp behavior that frustrates citizens who lack political connections.

Ethics Reform Remains Stalled

Despite mounting evidence of questionable trades, meaningful reform to ban congressional stock trading remains blocked. Some lawmakers who sold UnitedHealth stock, including Representatives Johnson and Landsman, publicly support trading bans, yet Congress refuses to pass legislation ending the practice. UnitedHealth currently holds a “Moderate Buy” rating with a consensus price target of $386, but faces continued pressure from Medicare headwinds, ACA rebates, and rising medical costs. The company reported rising medical cost ratios that concern analysts, yet continues receiving favorable ratings from major investment firms. Meanwhile, Medicare beneficiaries face flat reimbursement rates while politicians apparently time their exits to maximize personal profit, epitomizing government officials enriching themselves while constituents struggle with healthcare costs and investment losses.